Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.810
+0.130 (7.74%)
At close: Nov 20, 2026, 4:00 PM EST
1.870
+0.060 (3.31%)
After-hours: Nov 20, 2026, 7:59 PM EST
Pyxis Oncology Employees
Pyxis Oncology had 56 employees as of December 31, 2025. The number of employees increased by 12 or 27.27% compared to the previous year. That makes Pyxis Oncology the 34,528th largest employer in the world and 4,573rd in the United States.
Employees
56
Change (1Y)
12
Growth (1Y)
27.27%
Revenue / Employee
$197,107
Profits / Employee
-$1,548,357
Market Cap
216.49M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 56 | 12 | 27.27% |
| Dec 31, 2024 | 44 | -6 | -12.00% |
| Sep 30, 2024 | 54 | -13 | -19.40% |
| Jun 30, 2024 | 55 | -17 | -23.61% |
| Mar 31, 2024 | 51 | -22 | -30.14% |
| Dec 31, 2023 | 50 | -25 | -33.33% |
| Sep 30, 2023 | 67 | -6 | -8.22% |
| Jun 30, 2023 | 72 | 5 | 7.46% |
| Mar 31, 2023 | 73 | 9 | 14.06% |
| Dec 31, 2022 | 75 | 19 | 33.93% |
| Sep 30, 2022 | 73 | 28 | 62.22% |
| Jun 30, 2022 | 67 | 29 | 76.32% |
| Mar 31, 2022 | 64 | 26 | 68.42% |
| Dec 31, 2021 | 56 | - | - |
| Sep 30, 2021 | 45 | - | - |
| Jun 30, 2021 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Artiva Biotherapeutics | 134 |
| AC Immune | 122 |
| MediWound | 121 |
| Lineage Cell Therapeutics | 77 |
| Alpha Cognition | 71 |
| Bright Minds Biosciences | 26 |
| vTv Therapeutics | 26 |
PYXS News
- 2 days ago - Pyxis Oncology announces updated results from ongoing Phase 1 MICVO study - TheFly
- 2 days ago - William Blair upgrades Pyxis on head and neck cancer data - TheFly
- 2 days ago - Pyxis Oncology upgraded to Outperform from Market Perform at William Blair - TheFly
- 2 days ago - Pyxis Oncology Transcript: Study update - Transcripts
- 2 days ago - Pyxis Oncology Press release: Study update - Filings
- 2 days ago - Pyxis Oncology Slides: Study update - Filings
- 3 days ago - Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium - GlobeNewsWire
- 11 days ago - Pyxis Oncology Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts